Industry Press Releases

Bioness StimRouter™ Neuromodulation System Receives Aetna Coverage

Tuesday, Mar 28, 2017

Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, is pleased to announce that its StimRouter Neuromodulation System has received coverage from insurer Aetna Inc. effective March 8, 2017. With this coverage decision, Aetna considers the StimRouter medically necessary durable medical equipment (DME) for members with intractable neurogenic pain, also known as chronic pain of a peripheral nerve origin which the StimRouter is FDA cleared to treat.

Identified by patients as a severe and constant pain, intractable neurogenic pain is not relieved by traditional medical measures and largely treated with opioids. The StimRouter reduces pain by targeting the affected peripheral nerve and is a cost-effective and long-term alternative to immobilization, injections, and prescription opioids. With more than 23 million members, Aetna is the third largest private insurer in the United States and its decision to provide coverage of the StimRouter opens the door to a new treatment option for those members that are suffering from chronic peripheral nerve pain.

"Payers look at the long-term impact and cost effectiveness of devices closely when determining whether or not to extend coverage to members. Up until now patients suffering from intractable neurogenic pain have had limited treatment options and often had to pay for care that is considered experimental out of pocket," said Todd Cushman, President and CEO of Bioness. "We are very pleased that Aetna has recognized the value that the StimRouter and other peripherally implanted nerve stimulation systems bring to their members. Gaining coverage from payers has always been part of the StimRouter strategy and we believe this will support our efforts in attaining coverage from insurers."

Under Aetna's new policy, the StimRouter is considered medically necessary when members meet specific criteria. To learn more about these guidelines visit Aetna's website.

StimRouter was the first FDA cleared, minimally invasive, long-term, neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin. The StimRouter System received CE mark in February of 2014 and the patient-controlled medical device is an adjunct to other modes of therapy, and is being well received by patients and clinicians alike.

For more information on the StimRouter, please visit

About StimRouter™ Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients specific, changing pain management needs.

About Bioness, Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Bioness innovations have been implemented in the most prestigious and well-respected institutions around the globe with 17 of the top 20 rehabilitation hospitals in the United States currently using one or more Bioness solution. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at

Bioness Contact
Greg Lockman



Other Press Releases